All Stories

  1. Tracing the path from preschool wheezing to asthma
  2. Whole Exome Sequencing Identifies Epithelial and Immune Dysfunction‐Related Biomarkers in Food Protein‐Induced Enterocolitis Syndrome
  3. Parent's perception of respiratory syncytial virus and subsequent wheezing burden: A multi‐country cross‐sectional survey
  4. Recommendations for asthma monitoring in children: A PeARL document endorsed by APAPARI, EAACI, INTERASMA, REG, and WAO
  5. Recommendations for asthma monitoring in children.
  6. Component‐specific clusters for diagnosis and prediction of allergic airway diseases
  7. Association between polymorphisms on chromosome 17q12-q21 and rhinovirus-induced interferon responses
  8. Evaluation of measurement errors in the Patient‐Oriented Eczema Measure (POEM) outcome
  9. Component‐resolved diagnosis in childhood and prediction of asthma in early adolescence: A birth cohort study
  10. Understanding progression from pre‐school wheezing to school‐age asthma: Can modern data approaches help?
  11. Phenotype and endotype based treatment of preschool wheeze
  12. International consensus statement on allergy and rhinology: Allergic rhinitis – 2023
  13. Reply to Beck et al. and to Owora
  14. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA‐MeDALL hypothesis
  15. Evolution of Lung Function within Individuals: Clinical Insights and Data-driven Methods
  16. EAACI guidelines on environmental science in allergic diseases and asthma – Leveraging artificial intelligence and machine learning to develop a causality model in exposomics
  17. Environmental influences on childhood asthma: Allergens
  18. Will Oral Food Challenges Still Be Part of Allergy Care in 10 Years’ Time?
  19. Early childhood wheezing phenotypes and determinants in a South African birth cohort: longitudinal analysis of the Drakenstein Child Health Study
  20. Dog ownership in infancy is protective for persistent wheeze in 17q21 asthma-risk carriers
  21. Integrative transcriptomic analysis in human and mouse model of anaphylaxis identifies gene signatures associated with cell movement, migration and neuroinflammatory signalling
  22. Progenitor cell‐derived basophils: A novel barcoded passive degranulation assay in allergic diseases
  23. Evolution of Eczema, Wheeze, and Rhinitis from Infancy to Early Adulthood: Four Birth Cohort Studies
  24. A systems immunology approach to investigate cytokine responses to viruses and bacteria and their association with disease
  25. Childhood Asthma Incidence, Early and Persistent Wheeze, and Neighborhood Socioeconomic Factors in the ECHO/CREW Consortium
  26. Distinct airway epithelial immune responses after infection with SARS-CoV-2 compared to H1N1
  27. In vivo bronchial epithelial interferon responses are augmented in asthma on day 4 following experimental rhinovirus infection
  28. Defining the normal range of fractional exhaled nitric oxide in children: one size does not fit all
  29. Data‐driven research on eczema: Systematic characterization of the field and recommendations for the future
  30. Update in Asthma 2021
  31. WAO-ARIA consensus on chronic cough – Part III: Management strategies in primary and cough-specialty care. Updates in COVID-19
  32. Modeling Wheezing Spells Identifies Phenotypes with Different Outcomes and Genetic Associates
  33. Nonlinear effects of environment on childhood asthma susceptibility
  34. Short-chain fatty acid acetate triggers antiviral response mediated by RIG-I in cells from infants with respiratory syncytial virus bronchiolitis
  35. Life-threatening anaphylaxis to peanut — impossible to predict?
  36. Early life inter-kingdom interactions shape the immunological environment of the airways
  37. The Air We Breathe: Respiratory Impact of Indoor Air Quality in Chronic Obstructive Pulmonary Disease
  38. Early‐life predictors and risk factors of peanut allergy, and its association with asthma in later‐life: Population‐based birth cohort study
  39. Considering biomarkers in asthma disease severity
  40. Data-driven research on eczema: systematic characterization of the field and recommendations for the future
  41. Integration of Genomic Risk Scores to Improve the Prediction of Childhood Asthma Diagnosis
  42. The role of growth and nutrition in the early origins of spirometric restriction in adult life: a longitudinal, multicohort, population-based study
  43. Sex differences in innate anti-viral immune responses to respiratory viruses and in their clinical outcomes in a birth cohort study
  44. WAO-ARIA consensus on chronic cough – Part 1: Role of TRP channels in neurogenic inflammation of cough neuronal pathways
  45. WAO-ARIA consensus on chronic cough - Part II: Phenotypes and mechanisms of abnormal cough presentation — Updates in COVID-19
  46. Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper
  47. Modelling trajectories of parentally reported and physician‐confirmed atopic dermatitis in a birth cohort study*
  48. Rare variant analysis in eczema identifies exonic variants in DUSP1, NOTCH4 and SLC9A4
  49. Development of childhood asthma prediction models using machine learning approaches
  50. Spirometric phenotypes from early childhood to young adulthood: a Chronic Airway Disease Early Stratification study
  51. The change in exhaled nitric oxide in adolescents – a longitudinal cohort study
  52. Recurrent Severe Preschool Wheeze: From Prespecified Diagnostic Labels to Underlying Endotypes
  53. Four subtypes of childhood allergic rhinitis identified by latent class analysis
  54. Biomarkers of the Severity of Honeybee Sting Reactions and the Severity and Threshold of Systemic Adverse Events During Immunotherapy
  55. Atopic dermatitis or eczema? Consequences of ambiguity in disease name for biomedical literature mining
  56. Management of asthma in childhood: study protocol of a systematic evidence update by the Paediatric Asthma in Real Life (PeARL) Think Tank
  57. Childhood CCL18, CXCL10 and CXCL11 levels differentially relate to and predict allergy development
  58. Four childhood atopic dermatitis subtypes identified from trajectory and severity of disease and internally validated in a large UK birth cohort
  59. Childhood CCL18, CXCL10 and CXCL11 levels differentially relate to and predict allergy development
  60. Development of Childhood Asthma Prediction Models using Machine Learning Approaches
  61. Childhood asthma outcomes during the COVID‐19 pandemic: Findings from the PeARL multi‐national cohort
  62. Machine learning in asthma research: moving toward a more integrated approach
  63. Four subtypes of childhood allergic rhinitis identified by latent class analysis
  64. Acetate Triggers Antiviral Response Mediated by RIG-I in Cells from Infants with Respiratory Syncytial Virus Bronchiolitis
  65. The Montelukast Therapy in Asthmatic Children with and without Food Allergy: Does It Make Any Difference?
  66. Genetics of Asthma and Allergic Diseases
  67. Does death from Covid-19 arise from a multi-step process?
  68. The role of interferons in preschool wheeze
  69. Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies
  70. Circulating Chemokine Levels and the Development of Allergic Phenotypes from Infancy to Adolescence: A Population-Based Birth Cohort Study
  71. Asthma and Allergies: From Diagnosis-Based Approach towards Personalised Treatments
  72. Childhood Asthma: Low and Middle-Income Countries Perspective
  73. Childhood asthma outcomes during the COVID-19 pandemic: Findings from the PeARL multi-national cohort
  74. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries?
  75. ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice
  76. Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model
  77. Novel loci for childhood body mass index and shared heritability with adult cardiometabolic traits
  78. Connectivity patterns between multiple allergen specific IgE antibodies and their association with severe asthma
  79. Intranasal corticosteroids in allergic rhinitis in COVID‐19 infected patients: An ARIA‐EAACI statement
  80. Sex differences in innate anti-viral immune responses to respiratory viruses
  81. Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID‐19
  82. “Asthma” or “Asthma Spectrum Disorder”?
  83. Atopic phenotypes and their implication in the atopic march
  84. Impact of COVID-19 on Pediatric Asthma: Practice Adjustments and Disease Burden
  85. Targeting maternal immune function during pregnancy for asthma prevention in offspring: Harnessing the “farm effect”?
  86. Update in Asthma 2019
  87. Update on House Dust Mite Allergen Avoidance Measures for Asthma
  88. Is death from Covid-19 a multistep process?
  89. Research Priorities in Pediatric Asthma: Results of a Global Survey of Multiple Stakeholder Groups by the Pediatric Asthma in Real Life (PeARL) Think Tank
  90. Toward personalization of asthma treatment according to trigger factors
  91. Is diet partly responsible for differences in COVID-19 death rates between and within countries?
  92. Expression quantitative trait locus fine mapping of the 17q12–21 asthma locus in African American children: a genetic association and gene expression study
  93. Association of bacterial load in drinking water and allergic diseases in childhood
  94. national initiative in data science for health: an evaluation of the UK Farr Institute
  95. Comparative primary paediatric nasal epithelial cell culture differentiation and RSV-induced cytopathogenesis following culture in two commercial media
  96. Early-life inhalant allergen exposure, filaggrin genotype, and the development of sensitization from infancy to adolescence
  97. Interaction between filaggrin mutations and neonatal cat exposure in atopic dermatitis
  98. Allergic Endotypes and Phenotypes of Asthma
  99. Correlation between work impairment, scores of rhinitis severity and asthma using the MASK‐air ® App
  100. Longitudinal trajectories of severe wheeze exacerbations from infancy to school age and their association with early‐life risk factors and late asthma outcomes
  101. Comparative primary paediatric nasal epithelial cell culture differentiation and RSV-induced cytopathogenesis following culture in two commercial media
  102. Differential associations of allergic disease genetic variants with developmental profiles of eczema, wheeze and rhinitis
  103. Toward clinically applicable biomarkers for asthma: An EAACI position paper
  104. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline
  105. Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases
  106. ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions
  107. Dust-mite inducing asthma: what advice can be given to patients?
  108. Temporal association of the development of oropharyngeal microbiota with early life wheeze in a population-based birth cohort
  109. Distinguishing Wheezing Phenotypes from Infancy to Adolescence. A Pooled Analysis of Five Birth Cohorts
  110. Does understanding endotypes translate to better asthma management options for all?
  111. Blood Biomarkers of Sensitization and Asthma
  112. Epidemiology of Asthma in Children and Adults
  113. A trans-ancestral meta-analysis of genome-wide association studies reveals loci associated with childhood obesity
  114. Asthma: moving toward a global children's charter
  115. Nocturnal asthma is affected by genetic interactions between RORA and NPSR1
  116. The Early Growth Genetics (EGG) and EArly Genetics and Lifecourse Epidemiology (EAGLE) consortia: design, results and future prospects
  117. Adherence to treatment in allergic rhinitis using mobile technology. The MASK Study
  118. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma
  119. Different definitions of atopic dermatitis: Impact on prevalence estimates and associated risk factors
  120. The Syndrome We Agreed to Call Bronchiolitis
  121. Childhood Asthma: Advances Using Machine Learning and Mechanistic Studies
  122. Validation of childhood asthma predictive tools: A systematic review
  123. Individual risk assessment tool for school-age asthma prediction in UK birth cohort
  124. Pubertal height growth and lung function in adolescence and early adulthood
  125. Causes of variability in latent phenotypes of childhood wheeze
  126. Pediatric asthma: An unmet need for more effective, focused treatments
  127. Machine learning to identify pairwise interactions between specific IgE antibodies and their association with asthma: A cross-sectional analysis within a population-based birth cohort
  128. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence
  129. Trajectories of childhood immune development and respiratory health relevant to asthma and allergy
  130. Evolution of IgE responses to multiple allergen components throughout childhood
  131. Classification of Pediatric Asthma: From Phenotype Discovery to Clinical Practice
  132. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology
  133. Reply
  134. Vitamin D receptor genotype influences risk of upper respiratory infection
  135. Author Correction: Genome-wide association and HLA fine-mapping studies identify risk loci and genetic pathways underlying allergic rhinitis
  136. Mast cell activation test in the diagnosis of allergic disease and anaphylaxis
  137. Genome-wide association and HLA fine-mapping studies identify risk loci and genetic pathways underlying allergic rhinitis
  138. Lung function trajectories from pre-school age to adulthood and their associations with early life factors: a retrospective analysis of three population-based birth cohort studies
  139. Pulmonary epithelial barrier and immunological functions at birth and in early life - key determinants of the development of asthma?  A description of the protocol for the Breathing Together study
  140. Cytokine Responses to Rhinovirus and Development of Asthma, Allergic Sensitization, and Respiratory Infections during Childhood
  141. Development of allergic sensitization and its relevance to paediatric asthma
  142. Important and specific role for basophils in acute allergic reactions
  143. Temperature-controlled laminar airflow (TLA) device in the treatment of children with severe atopic eczema: Open-label, proof-of-concept study
  144. Epistasis between FLG and IL4R Genes on the Risk of Allergic Sensitization: Results from Two Population-Based Birth Cohort Studies
  145. International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
  146. Cat ownership, cat allergen exposure, and trajectories of sensitization and asthma throughout childhood
  147. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy
  148. Influenza burden, prevention, and treatment in asthma-A scoping review by the EAACI Influenza in asthma task force
  149. Geolocation with respect to personal privacy for the Allergy Diary app - a MASK study
  150. After asthma: redefining airways diseases
  151. Genome-wide search identifies new genetic variants associated with asthma risk.
  152. Non-parametric mixture models identify trajectories of childhood immune development relevant to asthma and allergy
  153. Predictive Modelling Strategies to Understand Heterogeneous Manifestations of Asthma in Early Life
  154. Detection of IgE Reactivity to a Handful of Allergen Molecules in Early Childhood Predicts Respiratory Allergy in Adolescence
  155. CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report
  156. Validation of the MASK-rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control
  157. Diagnosis of asthma in symptomatic children based on measures of lung function: an analysis of data from a population-based birth cohort study
  158. NIAID, NIEHS, NHLBI, and MCAN Workshop Report: The indoor environment and childhood asthma—implications for home environmental intervention in asthma prevention and management
  159. Features of asthma which provide meaningful insights for understanding the disease heterogeneity
  160. Basophils, high-affinity IgE receptors, and CCL2 in human anaphylaxis
  161. Shared genetic variants suggest common pathways in allergy and autoimmune diseases
  162. Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - EIP on AHA Twinning Reference Site (GARD research demonstration project)
  163. Epigenome-wide analysis links SMAD3 methylation at birth to asthma in children of asthmatic mothers
  164. Preventing Severe Asthma Exacerbations in Children. A Randomized Trial of Mite-Impermeable Bedcovers
  165. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis - A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement
  166. Formula one: best is no formula
  167. Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)
  168. Disaggregating asthma: Big investigation versus big data
  169. Epidemiology of Allergic Diseases
  170. International consensus (ICON) on: clinical consequences of mite hypersensitivity, a global problem
  171. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle
  172. Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies
  173. Erratum to: Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA
  174. Allergy in severe asthma
  175. Asthma phenotypes in childhood
  176. The importance of being earnest in epidemiology
  177. Building bridges for innovation in ageing: Synergies between Action Groups of the EIP on AHA
  178. A new framework for the interpretation of IgE sensitization tests
  179. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis
  180. Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)
  181. AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation
  182. Treatment of asthma in young children: evidence-based recommendations
  183. Insoluble and soluble roasted walnut proteins retain antibody reactivity
  184. Age, sex and the association between skin test responses and IgE titres with asthma
  185. Distinguishing benign from pathologic TH2 immunity in atopic children
  186. Evolution pathways of IgE responses to grass and mite allergens throughout childhood
  187. Genome-wide association analysis identifies three new susceptibility loci for childhood body mass index
  188. Relationship between cytokine expression patterns and clinical outcomes: two population‐based birth cohorts
  189. Patterns of IgE responses to multiple allergen components and clinical symptoms at age 11 years
  190. Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis
  191. Atopic Dermatitis and Respiratory Allergy: What is the Link
  192. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation
  193. Relation between circulating CC16 concentrations, lung function, and development of chronic obstructive pulmonary disease across the lifespan: a prospective study
  194. Distinguishing Asthma Phenotypes Using Machine Learning Approaches
  195. The Study Team for Early Life Asthma Research (STELAR) consortium ‘Asthma e-lab’: team science bringing data, methods and investigators together: Figure 1
  196. To what extent is allergen exposure a risk factor for the development of allergic disease?
  197. Developmental Profiles of Eczema, Wheeze, and Rhinitis: Two Population-Based Birth Cohort Studies
  198. A multicentre study of air pollution exposure and childhood asthma prevalence: the ESCAPE project
  199. A novel common variant in DCST2 is associated with length in early life and height in adulthood
  200. Peanut allergy: Effect of environmental peanut exposure in children with filaggrin loss-of-function mutations
  201. Polymorphisms of endotoxin pathway and endotoxin exposure:in vitroIgE synthesis and replication in a birth cohort
  202. Elemental Composition of Particulate Matter and the Association with Lung Function
  203. Cross-sectional association of dietary patterns with asthma and atopic sensitisation in childhood - in a cohort study
  204. Impact of rhinitis on asthma severity in school-age children
  205. Assessing the association of early life antibiotic prescription with asthma exacerbations, impaired antiviral immunity, and genetic variants in 17q21: a population-based birth cohort study
  206. Fraction of exhaled nitric oxide values in childhood are associated with 17q11.2-q12 and 17q12-q21 variants
  207. Integrated care pathways for airway diseases (AIRWAYS-ICPs)
  208. Effect of a novel temperature-controlled laminar airflow device on personal breathing zone aeroallergen exposure
  209. Genetic variants in endotoxin signalling pathway, domestic endotoxin exposure and asthma exacerbations
  210. Trajectories of Lung Function during Childhood
  211. Challenges in Interpreting Wheeze Phenotypes: The Clinical Implications of Statistical Learning Techniques
  212. Predicting phenotypes of asthma and eczema with machine learning
  213. Allergen Control for Prevention and Management of Allergic Diseases
  214. Challenges in Identifying Asthma Subgroups Using Unsupervised Statistical Learning Techniques
  215. A genome-wide association study identifies CDHR3 as a susceptibility locus for early childhood asthma with severe exacerbations
  216. EAACI position statement on asthma exacerbations and severe asthma
  217. Air Pollution Exposure and Lung Function in Children: The ESCAPE Project
  218. Differing associations of BMI and body fat with asthma and lung function in children
  219. Challenges in interpreting allergen microarrays in relation to clinical symptoms: A machine learning approach
  220. Characterizing wheeze phenotypes to identify endotypes of childhood asthma, and the implications for future management
  221. Long-term Exposure to PM 10 and NO 2 in Association with Lung Volume and Airway Resistance in the MAAS Birth Cohort
  222. Effects of long-term exposure to PM10and NO2on asthma and wheeze in a prospective birth cohort
  223. Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing
  224. Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology
  225. Breath metabolomic profiling by nuclear magnetic resonance spectroscopy in asthma
  226. Meta-analysis of genome-wide association studies identifies ten loci influencing allergic sensitization
  227. Interaction betweenglutathione S-transferasevariants, maternal smoking and childhood wheezing changes with age
  228. 17q12-21 and asthma: interactions with early-life environmental exposures
  229. Multiple atopy phenotypes and their associations with asthma: similar findings from two birth cohorts
  230. Pediatric asthma and development of atopy
  231. Methylation ofIL-2promoter at birth alters the risk of asthma exacerbations during childhood
  232. Asthma severity, polymorphisms in 20p13 and their interaction with tobacco smoke exposure
  233. Pooling Birth Cohorts in Allergy and Asthma: European Union-Funded Initiatives – A MeDALL, CHICOS, ENRIECO, and GA<sup>2</sup>LEN Joint Paper
  234. Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs
  235. Food protein–induced enterocolitis syndrome can occur in adults
  236. Does Pet Ownership in Infancy Lead to Asthma or Allergy at School Age? Pooled Analysis of Individual Participant Data from 11 European Birth Cohorts
  237. International consensus on (ICON) pediatric asthma
  238. Infantile and preschool asthma
  239. 17q12-21 Variants are associated with asthma and interact with active smoking in an adult population from the United Kingdom
  240. Gene–environment interactions in the development of asthma and atopy
  241. Genetic Variation in Vascular Endothelial Growth Factor-A and Lung Function
  242. Lung development and the role of asthma and allergy
  243. Estimated portion sizes in a school-aged population
  244. Erratum
  245. Davos Declaration: Allergy as a global problem
  246. Research needs in allergy: an EAACI position paper, in collaboration with EFA
  247. Severe Chronic Allergic (and Related) Diseases: A Uniform Approach – A MeDALL – GA<sup>2</sup>LEN – ARIA Position Paper
  248. The CREATE Project: Development of Certified Reference Materials for Allergenic Products and Validation of Methods for Their Quantification
  249. Meta-analysis of genome-wide association studies identifies three new risk loci for atopic dermatitis
  250. Treatment and secondary prevention effects of the probiotics Lactobacillus paracasei or Bifidobacterium lactis on early infant eczema: randomized controlled trial with follow-up until age 3 years
  251. Design and Recruitment for the GAP Trial, Investigating the Preventive Effect on Asthma Development of an SQ-Standardized Grass Allergy Immunotherapy Tablet in Children with Grass Pollen–Induced Allergic Rhinoconjunctivitis
  252. Differences in both prevalence and titre of specific immunoglobulin E among children with asthma in affluent and poor communities within a large town in Ghana
  253. Allergen-specific IgG antibody levels modify the relationship between allergen-specific IgE and wheezing in childhood
  254. Molecular diagnosis of peanut and legume allergy
  255. Peanut allergy: Overestimated in epidemiology or underdiagnosed in primary care?
  256. Quantification of specific IgE to whole peanut extract and peanut components in prediction of peanut allergy
  257. Asthma endotypes: A new approach to classification of disease entities within the asthma syndrome
  258. Effect of day care attendance on sensitization and atopic wheezing differs by Toll-like receptor 2 genotype in 2 population-based birth cohort studies
  259. Response
  260. Quantification of atopy, lung function and airway hypersensitivity in adults
  261. Development and implementation of guidelines in allergic rhinitis - an ARIA-GA2LEN paper
  262. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision
  263. Effect of addition of salmeterol versus doubling the dose of fluticasone propionate on specific airway resistance in children with asthma
  264. Allergy is an important factor in asthma exacerbation: A Pro/Con Debate
  265. Increased serum-soluble interleukin-5 receptor alpha level precedes the development of eczema in children
  266. Body mass index in young children and allergic disease: gender differences in a longitudinal study
  267. Beyond Atopy
  268. Changes in the FEV1/FVC ratio during childhood and adolescence: an intercontinental study
  269. Reference equations for specific airway resistance in children: the Asthma UK initiative
  270. Allergy or tolerance in children sensitized to peanut: Prevalence and differentiation using component-resolved diagnostics
  271. Dietary antioxidant intake, allergic sensitization and allergic diseases in young children
  272. Unmet needs in severe chronic upper airway disease (SCUAD)
  273. Prevention of allergic sensitization by environmental control
  274. Spirometry Centile Charts for Young Caucasian Children: The Asthma UK Collaborative Initiative
  275. Allergen Avoidance
  276. Long-Term Effects of Allergen Sensitization and Exposure in Adult Asthma
  277. Immune System Modeling with Infer.NET
  278. The European Union CREATE Project: A model for international standardization of allergy diagnostics and vaccines
  279. Day-care attendance, position in sibship, and early childhood wheezing: A population-based birth cohort study
  280. Early identification of atopy in the prediction of persistent asthma in children
  281. Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper
  282. Gene-Environment Interaction in the Onset of Eczema in Infancy: Filaggrin Loss-of-Function Mutations Enhanced by Neonatal Cat Exposure
  283. Dimensions of Respiratory Symptoms in Preschool Children
  284. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach
  285. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*
  286. EU Forum: The CREATE Project: development of certified reference materials for allergenic products and validation of methods for their quantification
  287. Bifidobacterium pseudocatenulatum is associated with atopic eczema: A nested case-control study investigating the fecal microbiota of infants
  288. Management of the asthmatic patient
  289. Quantification of atopy and the probability of rhinitis in preschool children: a population-based birth cohort study
  290. Two blind mice: New insights into mouse allergy
  291. Staphylococcus aureus sensitization and allergic disease in early childhood: Population-based birth cohort study
  292. Original article: Rhinoconjunctivitis in 5-year-old children: a population-based birth cohort study
  293. Active smoking among asthmatic youth?How concerned we need to be
  294. Exercise-Induced Bronchospasm and Atopy in Ghana: Two Surveys Ten Years Apart
  295. Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN)
  296. European birth cohort studies on asthma and atopic diseases: II. Comparison of outcomes and exposures – a GA2LEN initiative
  297. Endotoxin Exposure, CD14, and Allergic Disease
  298. Exhaled Breath Condensate pH and Childhood Asthma
  299. Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study
  300. Allergen avoidance in the secondary and tertiary prevention of allergic diseases: does it work?
  301. Atopic wheezing and early life antibiotic exposure: a nested case-control study
  302. Study of modifiable risk factors for asthma exacerbations: virus infection and allergen exposure increase the risk of asthma hospital admissions in children
  303. Dietary intake in sensitized children with recurrent wheeze and healthy controls: a nested case-control study
  304. Environmental exposures, genetic predisposition and allergic diseases: one size never fits all
  305. Intranasal air sampling in homes: Relationships among reservoir allergen concentrations and asthma severity
  306. Domestic allergen and endotoxin exposure and allergic sensitization in Cyprus
  307. Drugs used in paediatric allergy: should we conduct studies in children or extrapolate from adults?
  308. European birth cohort studies on asthma and atopic diseases: I. Comparison of study designs - a GA2LEN initiative
  309. Epidemiology of Allergic Disease
  310. Fungal contamination of bedding
  311. High-efficiency vacuum cleaners increase personal mite allergen exposure, but only slightly
  312. What are we learning from genetic cohort studies?
  313. Allergic disease in urban and rural populations: increasing prevalence with increasing urbanization
  314. IgE antibody quantification and the probability of wheeze in preschool children
  315. The effectiveness of measures to change the indoor environment in the treatment of allergic rhinitis and asthma: ARIA update (in collaboration with GA2LEN)
  316. Polymorphisms in A Disintegrin and Metalloprotease 33 ( ADAM33 ) Predict Impaired Early-Life Lung Function
  317. The information needs and preferred roles in treatment decision-making of parents caring for infants with atopic dermatitis: a qualitative study
  318. The role of allergen avoidance in the secondary prevention of atopic disorders
  319. Fecal microbiota in sensitized wheezy and non-sensitized non-wheezy children: a nested case-control study
  320. Pets and the development of allergic sensitization
  321. Potential roles in rhinitis for protease and other enzymatic activities of allergens
  322. Allergy and infection: understanding their relationship
  323. Effect of Mycobacterium vaccae on cytokine responses in children with atopic dermatitis
  324. Behavior Problems Antecede the Development of Wheeze in Childhood
  325. Wheeze Phenotypes and Lung Function in Preschool Children
  326. Relationship between exposure to domestic allergens and bronchial hyperresponsiveness in non-sensitised, atopic asthmatic subjects
  327. Asthma and sensitization in a community with low indoor allergen levels and low pet-keeping frequency
  328. Environmental allergen exposure, sensitisation and asthma: from whole populations to individuals at risk
  329. Lung Function at Age 3 Years
  330. World Allergy Organization Guidelines for Prevention of Allergy and Allergic Asthma
  331. Early Life Environmental Control
  332. Dampness in buildings as a risk factor for health effects, EUROEXPO: a multidisciplinary review of the literature (1998-2000) on dampness and mite exposure in buildings and health effects
  333. Response to ‘No clinical evidence base to support the hygiene hypothesis’ by C. P. van Schayck and J. A. Knottnerus
  334. No clinical evidence base to support the hygiene hypothesis
  335. Protective parasites and medicinal microbes? The case for the hygiene hypothesis
  336. Reported versus confirmed wheeze and lung function in early life
  337. Allergens, Viruses, and Asthma Exacerbations
  338. Childhood asthma
  339. Allergen avoidance in the primary prevention of asthma
  340. Can we prevent allergy?
  341. World Allergy Organization Guidelines for Prevention of Allergy and Allergic Asthma
  342. Manchester cohort
  343. The role of allergen avoidance in primary and secondary prevention
  344. Tobacco smoke exposure, wheeze, and atopy
  345. Relationship among pulmonary function, bronchial reactivity, and exhaled nitric oxide in a large group of asthmatic patients
  346. Urinary eosinophilic protein X, atopy, and symptoms suggestive of allergic disease at 3 years of age
  347. Primary and secondary prevention of allergic airway disease
  348. Stringent environmental control in pregnancy and early life: the long-term effects on mite, cat and dog allergen
  349. Childhood asthma, behavior problems, and family functioning
  350. Endotoxin contamination contributes to the pulmonary inflammatory and functional response to Aspergillus fumigatus extract inhalation in heaves horses
  351. Exposure and sensitization to indoor allergens: Association with lung function, bronchial reactivity, and exhaled nitric oxide measures in asthma
  352. Control of Exposure to Mite Allergen and Allergen-Impermeable Bed Covers for Adults with Asthma
  353. Air filtration units in homes with cats: can they reduce personal exposure to cat allergen?
  354. High-efficiency particulate arrest–filter vacuum cleaners increase personal cat allergen exposure in homes with cats
  355. Childhood asthma
  356. Current mite, cat, and dog allergen exposure, pet ownership, and sensitization to inhalant allergens in adults
  357. Early pet exposure: friend or foe?
  358. Clinical effects of air filters in homes of asthmatic adults sensitized and exposed to pet allergens
  359. Skin test reactivity to natural and recombinant Blomia and Dermatophagoides spp. allergens among mite allergic patients in the UK
  360. The National Asthma Campaign Manchester Asthma and Allergy Study
  361. Clostridium difficile , atopy and wheeze during the first year of life
  362. Household characteristics and mite allergen levels in Manchester,UK
  363. The effect of allergen exposure in early childhood on the development of atopy
  364. Preventive measures and their effects
  365. Seasonal variability in exercise test responses in Ghana
  366. Specific airway resistance in 3-year-old children: a prospective cohort study
  367. Personal exposure to house dust mite allergen in bed: nasal air sampling and reservoir allergen levels
  368. Controlling indoor allergens
  369. Is allergen avoidance effective?*
  370. Lung function at one month of age as a risk factor for infant respiratory symptoms in a high risk population
  371. Synergism between allergens and viruses and risk of hospital admission with asthma: case-control study
  372. Array-based diagnostic gene-expression score for atopy and asthma
  373. Environmental allergens in Kuwait
  374. Independent effects of intestinal parasite infection and domestic allergen exposure on risk of wheeze in Ethiopia: a nested case-control study
  375. Decreased prevalence of sensitization to cats with high exposure to cat allergen
  376. The role of indoor allergen exposure in the development of sensitization and asthma
  377. The role of indoor allergen exposure in the development of sensitization and asthma
  378. Pet allergen levels in homes in Ghana and the United Kingdom
  379. Risk factors for asthma in urban Ghana
  380. Avoidance of allergens and air pollutants in respiratory allergy
  381. Lymphoproliferative responses in cord blood and at one year: no evidence for the effect of in utero exposure to dust mite allergens
  382. Effect of environmental manipulation in pregnancy and early life on respiratory symptoms and atopy during first year of life: a randomised trial
  383. Housing characteristics and mite allergen levels: to humidity and beyond
  384. On allergens and asthma (again): does exposure to allergens in homes exacerbate asthma?
  385. Exposure and sensitization in infants and children
  386. Exposure and sensitization in infants and children
  387. NAC Manchester Asthma and Allergy Study (NAC MAAS): risk factors for asthma and allergic disorders in adults
  388. Apoptosis signals in atopy and asthma measured with cDNA arrays
  389. Environmental allergen exposure and asthma: prospects for primary prevention
  390. The −403 G→A promoter polymorphism in the RANTES gene is associated with atopy and asthma
  391. Chapter 1: Genetic and Environmental Influences
  392. Prevention of Allergy and Asthma
Interim Report
  393. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study
  394. Synthetic pillows contain higher levels of cat and dog allergen than feather pillows
  395. Manchester Asthma and Allergy Study: Low-allergen environment can be achieved and maintained during pregnancy and in early life
  396. Clinical Effects of Allergen Avoidance
  397. Allergen avoidance: does it work?
  398. Dust mite allergens are carried on not only large particles
  399. Exhaled Nitric Oxide, Sensitization, and Exposure to Allergens in Patients with Asthma Who Are Not Taking Inhaled Steroids
  400. Relationship between mite, cat, and dog allergens in reservoir dust and ambient air
  401. Attempting to control mite allergens with mechanical ventilation and dehumidification in British houses
  402. The effect of air filtration on airborne dog allergen
  403. Mite allergens in feather and synthetic pillows
  404. Vacuum cleaners and airborne dog allergen
  405. Washing the dog reduces dog allergen levels, but the dog needs to be washed twice a week
  406. Sensitivity and exposure to indoor allergens in adults with differing asthma severity
  407. Feather or synthetic? That is the question
  408. The effect of dry heat on mite, cat, and dog allergens
  409. Importance of indoor allergens in the induction of allergy and elicitation of
  410. Risk levels for mite allergens. Are they meaningful?
  411. Indoor environmental factors and respiratory illness
  412. Role of the indoor environment in determining the severity of asthma
  413. Variability of house-dust-mite allergen levels within carpets
  414. ABC of allergies: Avoiding exposure to indoor allergens
  415. Allergen avoidance in the treatment of asthma and atopic disorders
  416. Distribution, aerodynamic characteristics, and removal of the major cat allergen Fel d 1 in British homes
  417. Domestic allergens in public places III: house dust mite, cat, dog and cockroach allergens in British hospitals
  418. Exercise induced bronchospasm in Ghana: differences in prevalence between urban and rural schoolchildren
  419. Aerodynamic properties of the major dog allergen Can f 1: distribution in homes, concentration, and particle size of allergen in the air.
  420. Domestic allergens in public places II: dog (Can f 1) and cockroach (Bla g 2) allergens in dust and mite, cat, dog and cockroach allergens in the air in public buildings
  421. New mattresses: how fast do they become a significant source of exposure to house dust mite allergens?
  422. Domestic allergens in public places II: dog (Can f 1) and cockroach (Bla g 2) allergens in dust and mite, cat, dog and cockroach allergens in the air in public buildings
  423. New mattresses: how fast do they become a significant source of exposure to house dust mite allergens?
  424. Reduction in humidity as a method of controlling mites and mite allergens: the use of mechanical ventilation in British domestic dwellings
  425. Reduction in humidity as a method of controlling mites and mite allergens: the use of mechanical ventilation in British domestic dwellings
  426. Exposure to house dust mite allergens and the clinical activity of asthma
  427. Asthmatic bronchial hyperresponsiveness varies with ambient levels of summertime air pollution
  428. Evaluating exposure to mite allergens
  429. GR106642X: a new, non-ozone depleting propellant for inhalers
  430. Portable dehumidifiers in the control of house dust mites and mite allergens
  431. House dust mite and cat allergen in different indoor environments
  432. Assessing Exercise-induced Bronchospasm
  433. Exercise Testing Revisited
  434. Animal Allergens
  435. Does Allergen Avoidance Help? What are the Practical Measures that Patients can Take?